The anti-inflammatory effects of therapies for ocular allergy

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 9, 2013, Pages 786-793

  Mantelli, Flavio ^a   Calder, Virginia L ^b   Bonini, Stefano ^c  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZELASTINE; CYCLOSPORIN A; DEXAMETHASONE; EMEDASTINE; EOSINOPHIL CATIONIC PROTEIN; EPINASTINE; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; KETOROLAC TROMETAMOL; KETOTIFEN; LEVOCABASTINE; LODOXAMIDE; LODOXAMIDE TROMETAMOL; LOTEPREDNOL; MAJOR BASIC PROTEIN; NEDOCROMIL; OLOPATADINE; PEMIROLAST; PHENIRAMINE; PHENIRAMINE MALEATE; PREDNISONE; RIMEXOLONE; TACROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ANTERIOR EYE CHAMBER; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; ATOPIC KERATOCONJUNCTIVITIS; BLOOD VESSEL PERMEABILITY; CHEMOSIS; CHRONIC URTICARIA; CLINICAL PRACTICE; CONJUNCTIVA EPITHELIUM; DERMATOPHAGOIDES; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFECT; EOSINOPHIL; EYE SWELLING; FEVER; FOOD ALLERGY; HISTAMINE RELEASE; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MAINTENANCE THERAPY; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR RELEASE; MOLECULAR INTERACTION; OCULAR PRURITUS; PERENNIAL ALLERGIC CONJUNCTIVITIS; PERENNIAL RHINITIS; PROTEIN EXPRESSION; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; TOPICAL TREATMENT; URTICARIA; VERNAL CONJUNCTIVITIS;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DRUG DESIGN; EOSINOPHILS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTES; MAST CELLS;

EID: 84887043440     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0161     Document Type: Review

References (76)

1. Bielory, L. Ocular allergy overview. Immunol. Allergy Clin. North Am. 28:1-23, 2008. (Pubitemid 351241112)
2. Bielory, L. Ocular allergy treatment. Immunol. Allergy Clin. North Am. 28:189-224, 2008. (Pubitemid 351241103)
3. Stahl, J.L., and Barney, N.P. Ocular allergic disease. Curr. Opin. Allergy Clin. Immunol. 4:455-459, 2004. (Pubitemid 39274090)
4. Trocme, S.D., and Sra, K.K. Spectrum of ocular allergy. Curr. Opin. Allergy Clin. Immunol. 2:423-427, 2002. (Pubitemid 35239525)
5. Anderson, D.F. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies. Clin. Exp. Allergy 31:823-826, 2001. (Pubitemid 34204253)
6. Bielory, L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 62:1611-1634, 2002. (Pubitemid 34848369)
7. Bielory, L., Katelaris, C.H., Lightman, S., and Naclerio, R.M. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed. 9:35, 2007.
8. Mantelli, F., Lambiase, A., Bonini, S., and Bonini, S. Clinical trials in allergic conjunctivits: a systematic review. Allergy 66:919-924, 2011.
9. Owen, C.G., Shah, A., Henshaw, K., Smeeth, L., and Sheikh, A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br. J. Gen. Pract. 54:451-456, 2004. (Pubitemid 38771894)
10. Anderson, D.F., MacLeod, J.D., Baddeley, S.M., Bacon, A.S., McGill, J.I., Holgate, S.T., and Roche, W.R. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin. Exp. Allergy 27:1060-1066, 1997. (Pubitemid 27421835)
11. Suzuki, S., Goto, E., Dogru, M., Asano-Kato, N., Matsumoto, Y., Hara, Y., Fujishima, H., and Tsubota, K. Tear film lipid layer alterations in allergic conjunctivitis. Cornea 25:277-280, 2006.
12. Trocme, S.D., Leiferman, K.M., George, T., Bonini, S., Foster, C.S., Smit, E.E., Sra, S.K., Grabowski, L.R., and Dohlman, C.H. Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis. Curr. Eye Res. 26:319-325, 2003. (Pubitemid 36920833)
13. Leonardi, A., Jose, P.J., Zhan, H., and Calder, V.L. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 110:487-492, 2003. (Pubitemid 36262729)
14. Leonardi, A., De Dominicis, C., and Motterle, L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr. Opin. Allergy Clin. Immunol. 7:429-435, 2007. (Pubitemid 47415288)
15. Leonardi, A., Fregona, I.A., Plebani, M., Secchi, A.G., and Calder, V.L. Th1-and Th2-type cytokines in chronic ocular allergy. Graefes Arch. Clin. Exp. Ophthalmol. 244:1240-1245, 2006. (Pubitemid 44463460)
16. Leonardi, A. Emerging drugs for ocular allergy. Expert Opin. Emerg. Drugs 10:505-520, 2005. (Pubitemid 41176284)
17. Dogru, M., Okada, N., Asano-Kato, N., Tanaka, M., Igarashi, A., Takano, Y., Fukagawa, K., Shimazaki, J., Tsubota, K., and Fujishima, H. Atopic ocular surface disease: implications on tear function and ocular surface mucins. Cornea 24:S18-S23, 2005. (Pubitemid 41688551)
18. Leonardi, A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog. Retin. Eye Res. 21:319-339, 2002. (Pubitemid 34614554)
19. Kocabeyoglu, S., Bozkurt, B., Bilen, O., Irkec, M., and Orhan, M. Serum allergen specific immunoglobulin E levels in patients with allergic conjunctivitis. Eur. J. Ophthalmol. 18:675-679, 2008.
20. Mantelli, F., Santos, M.S., Petitti, T., Sgrulletta, R., Cortes, M., Lambiase, A., and Bonini, S. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br. J. Ophthalmol. 91:1656-1661, 2007. (Pubitemid 350207394)
21. Sacchetti, M., Lambiase, A., Mantelli, F., Deligianni, V., Leonardi, A., and Bonini, S. Tailored approach to the treatment of vernal keratoconjunctivitis. Ophthalmology 117:1294-1299, 2010.
22. Dart, J.K., Buckley, R.J., Monnickendan, M., and Prasad, J. Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis. Trans. Ophthalmol. Soc. U K 105:513-520, 1986.
23. Ehlers, W.H., and Donshik, P.C. Allergic ocular disorders: a spectrum of diseases. CLAO J. 18:117-124, 1992.
24. Hodges, M.G., and Keane-Myers, A.M. Classification of ocular allergy. Curr. Opin. Allergy Clin. Immunol. 7:424-428, 2007. (Pubitemid 47415287)
25. Uchio, E., Kimura, R., Migita, H., Kozawa, M., and Kadonosono, K. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch. Clin. Exp. Ophthalmol. 246:291-296, 2008. (Pubitemid 351149635)
26. Tuft, S.J., Kemeny, D.M., Dart, J.K., and Buckley, R.J. Clinical features of atopic keratoconjunctivitis. Ophthalmology 98:150-158, 1991.
27. Bonini, S., Lambiase, A., Matricardi, P., Rasi, G., and D'Amato, M. Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Curr. Probl. Dermatol. 28:88-94, 1999.
28. Mantelli, F., Lambiase, A., and Bonini, S. A simple and rapid diagnostic algorithm for the detection of ocular allergic diseases. Curr. Opin. Allergy Clin. Immunol. 9:471-476, 2009.
29. Bielory, L. Allergic diseases of the eye. Med. Clin. North Am. 90:129-148, 2006. (Pubitemid 41682034)
30. Bonini, S., Lambiase, A., Marchi, S., Pasqualetti, P., Zuccaro, O., Rama, P., Magrini, L., Juhas, T., and Bucci, M.G. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 107:1157-1163, 2000.
31. Bielory, L., Lien, K.W., and Bigelsen, S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65:215-228, 2005. (Pubitemid 40139383)
32. Lambiase, A., Micera, A., and Bonini, S. Multiple action agents and the eye: do they really stabilize mast cells? Curr. Opin. Allergy Clin. Immunol. 9:454-465, 2009.
33. Hingorani, M., Calder, V., Jolly, G., Buckley, R.J., and Lightman, S.L. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J. Allergy Clin. Immunol. 102:821-830, 1998. (Pubitemid 28543533)
34. Kumagai, N., Fukuda, K., Fujitsu, Y., Yamamoto, K., and Nishida, T. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Progr. Retin. Eye Res. 25:165-187, 2006. (Pubitemid 43227843)
35. Baudouin, C., et al. Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. Graefes Arch. 238:900-904, 2000.
36. Calder, V.L., et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin. Exp. Allergy 29:1214-1222, 1999. (Pubitemid 29406469)
37. Abelson. M.B., George, M.A., Schaefer, K., and Smith, L.M. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J. Allergy Clin. Immunol. 94:458-464, 1994.
38. Ahluwalia, P., Anderson, D.F., Wilson, S.J., McGill, J.I., and Church, M.K. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J. Allergy Clin. Immunol. 108:449-454, 2001. (Pubitemid 32881069)
39. Abelson, M.B., Gomes, P., Crampton, H.J., Schiffman, R.M., Bradford, R.R., and Whitcup, S.M. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin. Ther. 26:35-47, 2004. (Pubitemid 38241521)
40. Greiner, J.V., and Udell, I.J. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 27:568-77, 2005. (Pubitemid 40835967)
41. Tashiro, M., Sakurada, Y., Mochizuki, H., Horikawa, E., Maruyama, M., Okamura, N., Watanuki, S., Arai, H., Itoh, M., and Yanai, K. Effects of a sedative antihistamine, Dchlorpheniramine, on regional cerebral perfusion and performance during simulated car driving. Hum. Psychopharmacol. 23:139-150, 2008. (Pubitemid 351359586)
42. Abelson, M.B., Berdy, G.J., Mundorf, T., Amdahl, L.D., and Graves, A.L. Pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J. Ocul. Pharmacol. Ther. 18:475-488, 2002. (Pubitemid 37420256)
43. Bonini, S., Schiavone, M., Bonini, S., Magrini, L., Lischetti, P., Lambiase, A., and Bucci, M.G. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 104:849-853, 1997. (Pubitemid 27200885)
44. Fahy, G.T., Easty, D.L., Collum, L.M., Benedict-Smith, A., Hillery, M., and Parsons, D.G. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study. Eur. J. Ophthalmol. 2:144-149, 1992.
45. Caldwell, D.R., Verin, P., Hartwich-Young, R., Meyer, S.M., and Drake, M.M. Efficacy and safety of lodoxamide 0.1% vs. cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am. J. Ophthalmol. 113:632-637, 1992.
46. Abelson, M.B., and Spitalny, L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol. 125:797-804, 1998. (Pubitemid 28283741)
47. Mandal, R., Maiti, P., Sasmal, N.K., Sinha, N., Gupta, A., Das, K.S., and Biswas, M.C. Ocular effects of long term use of topical steroids among children and adolescents with vernal keratoconjunctivitis: a prospective observational study. J. Indian Med. Assoc. 109:708-710, 712-713, 2011.
48. Fujishima, H., Fukagawa, K., Takano, Y., Tanaka, M., Okamoto, S., Miyazaki, D., Yamada, J., Fukushima, A., Uchio, E., and Nakagawa, Y. Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 25:265-270, 2009.
49. Mohan, R., and Muralidharan, A.R. Steroid induced glaucoma and cataract. Indian J. Ophthalmol. 37:13-16, 1989. (Pubitemid 19252373)
50. Comstock, T.L., and Decory, H.H. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int. J. Inflam.2012:789623, 2012.
51. Fan,D.S., Yu, C.B., Chiu, T.Y., Wong, C.Y.,Ng, J.S., Pang, C.P., and Lam, D.S. Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch. Ophthalmol. 121:1716-1721, 2003. (Pubitemid 37517438)
52. Samudre, S.S., Lattanzio Jr., F.A., Williams, P.B., and Sheppard Jr., J.D. Comparison of topical steroids for acute anterior uveitis. J. Ocul. Pharmacol. Ther. 20:533-547, 2004. (Pubitemid 39628498)
53. Gong, L., Sun, X., Qu, J., Wang, L., Zhang, M., Zhang, H., Wang, L., Gu, Y., Elion-Mboussa, A., Roy, L., and Zhu, B. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin. Ther. 34:1259-1272, 2012.
54. Maier, A.K., Ozlü gedik, S., Rottler, J., Heussen, F.M., Klamann, M.K., Huber, K.K., Joussen, A.M., and Winterhalter, S. Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis. Cornea 30:1398-405, 2011.
55. Lambiase, A., Leonardi, A., Sacchetti, M., Deligianni, V., Sposato, S., and Bonini, S. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J. Allergy Clin. Immunol. 128:896-897, 2011.
56. Larson, T., Nussenblatt, R.B., and Sen, H.N. Emerging drugs for uveitis. Expert Opin. Emerg. Drugs 16:309-322, 2011.
57. Taddio, A., Cimaz, R., Caputo, R., de Libero, C., Di Grande, L., Simonini, G., Mori, F., Novembre, E., and Pucci, N. Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series. Pediatr. Rheumatol. Online J. 9:34, 2011.
58. Canonica, G.W., Ciprandi, G., Petzold, U., Kolb, C., Ellers-Lenz, B., and Hermann, R. Topical azelastine in perennial allergic conjunctivitis. Curr. Med. Res. Opin. 19:321-329, 2003. (Pubitemid 36827841)
59. Friedlaender, M.H., Harris, J., LaVallee, N., Russell, H., and Shilstone, J. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 107:2152-2157, 2000.
60. Hoshino, M., and Nakamura, Y. The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int. Arch. Allergy Immunol. 114:285-292, 1997. (Pubitemid 27448444)
61. Kempuraj, D., Huang, M., Kandere-Grzybowska, K., Basu, S., Boucher, W., Letourneau, R., Athanassiou, A., and Theoharides, T.C. Azelastine inhibits secretion of IL-6, TNFalpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int. Arch. Allergy Immunol. 132:231-239, 2003. (Pubitemid 37499979)
62. McTavish, D., and Sorkin, E.M. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 38:778-800, 1989. (Pubitemid 19285393)
63. Chand, N., Pillar, J., Diamantis, W., Perhach Jr., J.L., and Sofia, R.D. Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action. Eur. J. Pharmacol. 96:227-233, 1983. (Pubitemid 14216969)
64. Chand, N., Pillar, J., Diamantis, W., and Sofia, R.D. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 16:318-322, 1985. (Pubitemid 15040971)
65. Corin, R.E. Nedocromil sodium: a review of the evidence for a dual mechanism of action. Clin. Exp. Allergy 30:461-468, 2000. (Pubitemid 30253183)
66. Hoyos, L., Norris, A., and Vargaftig, B.B. Effects of nedocromil sodium on antigen-induced conjunctivitis in guinea pigs. Adv. Ther. 17:1-6, 2000. (Pubitemid 30180870)
67. Ahluwalia, P. Anderson, D.F., Wilson, S.J., McGill, J.I., and Church, M.K. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J. Allergy Clin. Immunol. 108:449-454, 2001. (Pubitemid 32881069)
68. Orfeo, V., Vardaro, A., Lena, P., Mensitieri, I., Tracey, M., and De Marco, R. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Eur. J. Ophthalmol. 12:262-266, 2002.
69. Sharif, N.A., Su, S.X., and Yanni, J.M. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J. Ocul. Pharmacol. 10:653-664, 1994.
70. el-Shazly, A.E., Masuyama, K., Samejima, Y., Eura, M., and Ishikawa, T. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. Immunopharmacol. Immunotoxicol. 18:587-595, 1996. (Pubitemid 26391821)
71. Saito, T., Hagihara, A., Igarashi, N., Matsuda, N., Yamashita, A., Ito, K., Mio, M., and Tasaka, K. Inhibitory effects of emedastine difumarate on histamine release. Jpn. J. Pharmacol. 62:137-143, 1993. (Pubitemid 23218232)
72. Andoh, T., and Kuraishi, Y. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice. Eur. J. Pharmacol. 406:149-152, 2000.
73. Grant, S.M., Goa, K.L., Fitton, A., and Sorkin, E.M. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 40:412-448, 1990.
74. Schoch, C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J. Ocul. Pharmacol. Ther. 19:75-81, 2003. (Pubitemid 36249882)
75. Martin, A.P., Urrets-Zavalia, J., Berra, A., Mariani, A.L., Gallino, N., Gomez Demel, E., Gagliardi, J., Baena-Cagnani, C.E., Urrets-Zavalia, E., and Serra, H.M. The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. BMC Ophthalmol. 3:2, 2003.
76. Woodward, D.F., Nieves, A.L., and Friedlander, M.H. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J. Pharmacol. Exp. Ther. 279:137-142, 1996. (Pubitemid 27166904)